Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥3,640 JPY
Change Today -70.00 / -1.89%
Volume 914.2K
As of 2:00 AM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1-1 Nihonbashi-Muromachi 2-Chome


Tokyo, 103-8324


Phone: 81 3 3281 6611

Fax: 81 3 3281 6607

cation of rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis, and systemic-onset juvenile idiopathic arthritis. Overseas, Actemra was approved in the European Union in January 2009 (European product name: RoActemra). R1594: R1594 is a second-generation humanized anti-CD20 monoclonal antibody that binds to a particular protein (the CD20 antigen) on the surface of human B cell lymphocytes, activating the immune system to eliminate the marked cells. R1594 is being studied for various autoimmune diseases by Roche Group companies. Japan is participating in an ongoing global phase III study of R1594 for rheumatoid arthritis. OTHER FIELDS Chronic Hepatitis C Pegasys/Copegus: Pegasys (generic name: peginterferon alfa-2a) enables sustained therapeutic concentrations to be achieved with once-weekly administration. Copegus (generic name: ribavirin) is a chronic hepatitis C treatment that synergistically improves the antiviral effect when used in combination with interferon. The company has obtained approval for Copegus and launched it in combination with Pegasys for the treatment of patients with chronic hepatitis C serogroup 1 infection and high viral load, or those who have either not responded to, or have relapsed following, interferon monotherapy. It offers peginterferon for both monotherapy and combination therapy. NA808: NA808 is a small-molecule compound that is intended to prove effective as a treatment for chronic hepatitis C. The drug acts on the body, not the virus, to inhibit the growth of the virus. Influenza Tamiflu: Tamiflu is an oral anti-influenza agent that is used against both type A and type B infections. It inhibits viral replication by binding to and blocking the action of neuraminidase, an enzyme essential for the multiplication of the influenza virus. Angina Pectoris Sigmart: Anti-anginal agent Sigmart is a drug that overcomes the flaws of nitric acid compounds, such as nitroglycerin and treats various types of angina pectoris. Castleman’s Disease Actemra: Actemra is a humanized anti-human IL-6 receptor monoclonal antibody produced using genetical recombination technology. With a mechanism of action that inhibits the receptor for IL-6, a type of cytokine, the drug improves Castleman’s disease symptoms. Diabetes R1583 (ITM-077): R1583 is a new compound that mimics GLP-1 (glucagon-like peptide 1), a hormone that stimulates the secretion of insulin. As GLP-1 stimulates insulin secretion when blood sugar levels are too high, there is little risk of the drug causing low blood sugar. R1583 is formulated using technology from Ipsen that enables maintenance of therapeutic concentrations for extended periods. R1583 is being co-developed in Japan with Teijin Pharma Limited. CSG452 (R7201): An oral preparation that reduces blood sugar level, CSG453 is intended for the treatment for type 2 diabetes. The company has licensed the drug to Roche and conducting phase I domestic clinical trials. R1579: R1579 is a dipeptidyl peptidase-IV (DPP-IV) inhibitor licensed from Roche. The company is conducting phase I domestic clinical trials for the treatment of type 2 diabetes. Schizophrenia R1678: R1678, a small-molecule compound licensed from Roche, is intended for the treatment of schizophrenia. The company is conducting global phase II clinical trials. History Chugai Pharmaceutical Co., Ltd. was founded in 1925.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4519:JP ¥3,640.00 JPY -70.00

4519 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.82 USD +0.69
Eli Lilly & Co $87.52 USD +2.34
Merck KGaA €77.45 EUR -0.202
Sanofi €84.98 EUR +0.37
Teva Pharmaceutical Industries Ltd $60.06 USD +1.56
View Industry Companies

Industry Analysis


Industry Average

Valuation 4519 Industry Range
Price/Earnings 38.9x
Price/Sales 4.2x
Price/Book 3.3x
Price/Cash Flow 39.9x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHUGAI PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at